Antioxidants containing selenium impact on unexplained oligohydramnios
Keywords:Selenium, Amniotic fluid index, Oligohydramnios, Fetal weight, APGAR score
Background: Oligohydramnios is a significant morbidity during pregnancy that may affect fetal growth and functions and the presented work was an effort to test the addition of selenium for the correction and regaining normal liquor.
Methods: Cases recruited from those attending Zinat al-Hayat hospitals and diagnosed with unexplained oligohydramnios after exclusion of prom postdates pregnancy induced hypertension Then final 100 cases divided into two groups group one control: 50 controls that followed healthy diet and a positive mindset only group two cases: 50 who followed healthy lifestyle plus adding selenium ace tablets once daily. Cases and controls followed by ultrasound evaluation with calculation of AFI and fetal weight.
Results: Regarding improvement in amniotic index to be more than 5, there were 40 cases out of 50 in cases compared to 25 in controls with p=0.001 a high statistical difference that signified positive impact on the amount of amniotic fluid, regarding amniotic fluid particle diameter it was present in 22 out of 50 in controls compared to 8 only in cases with p=0.002,Regarding birth weight of, more than 2500 gm. there were 20 out of 50 in controls compared to 35 out of 50 in cases with intervention and p=0.002. Regarding APGAR score below 6 there were 15 in controls compared to only 3 in cases with p=0.001, regarding neonatal incubation there were 10 in controls compared to one in selenium group with p=0.004.
Conclusions: adding selenium ace tablets in cases of unexplained oligohydramnios had a promising result and a positive impact on amniotic fluid index and neonatal outcomes
Gizzo S, Noventa M, Vitagliano A, Dall'Asta A, D'Antona D, Aldrich CJ et al. An update on maternal hydration strategies for amniotic fluid improvement in isolated Oligohydramnios and Normohydramnios: evidence from a systematic review of literature and meta-analysis. PLoS One. 2015;10:e0144334.
Goldenberg RL, Nathan R, Swanson D, Saleem S, Mirza W, Esamai F et al. Routine antenatal ultrasound in low- and middle-income countries: first look - a cluster randomised trial. BJOG. 2018;125:1591-9.
Hesson A, Langen E. Outcomes in oligohydramnios: the role of etiology in predicting pulmonary morbidity/mortality. J Perinat Med. 2018;46:948-50.
Mathuriya G, Verma M, Rajpoot S. Comparative study of maternal and fetal outcome between low and normal amniotic fluid index at term. Int J Reprod contraception Obstet Gynecol. 2017;6:640.
Madhavi K, Pc R, Professor A. Clinical study of oligohydramnios, mode of delivery and perinatal outcome. IOSR J Dent Med Sci. 2015;14:2279-861.
12. Xiao XM, Li LP. L-Arginine treatment for asymmetric fetal growth restriction. Int J Gynecol Obstet. 2005;88:15-8.
Soni A, Garg S, Patel K, Patel Z. Role of L-arginine in oligohydramnios. J Obstetrics Gynecol Ind. 2016;66(1):279-83.
Mittal R, Satwant K, Mittal N. L-arginine supplementation in intrauterine growth retardation. Int J Pharm Chem Sci. 2013;2(3):1569-72.
Viviana DP, Giuseppe C, Fabio F. Clinical use of nitric oxide donors and l-arginine in obstetric. J Mater Fetal Neonatal Med. 2007;20(8):569-79.
Lampariello C, De Blasio A, Merenda A. Use of l-arginine in intrauterine growth retardation (IUGR): authors’ experience. Minerva Ginecol. 1997;49:577-81.
Staff AC, Berge L, Haugen G. Dietary supplementation with l-arginine or placebo in women with pre-eclampsia. Acta Obstet Gynecol Scand. 2004;83:103-7.
Thureen PJ, Baron KA, Fennessey PV. Ovine placental and fetal arginine metabolism at normal and increased maternal plasma arginine concentrations. Pediatr Res. 2002;51:464-71.
Xiao XM, Li LP. L-Arginine treatment for asymmetric fetal growth restriction. Int J Gynecol Obstet. 2005;88:15-8.
Myatt L, Rosenfield RB, Eis ALW. Nitrotyrosine residues in placenta evidence of peroxynitrite formation and action. Hypertension. 1996;28:488-93.